Millions of people in the third world die from diseases that are rare in the first world--diseases like malaria, tuberculosis, and schistosomiasis. AIDS, which is now usually treated in rich countries, still ravages the world's poor. Vaccines offer the best hope for controlling these diseases and could dramatically improve health in poor countries. But developers have little incentive to undertake the costly and risky research needed to develop vaccines. This is partly because the potential consumers are poor, but also because governments drive down prices.
In Strong...
Millions of people in the third world die from diseases that are rare in the first world--diseases like malaria, tuberculosis, and schistosomiasis....
Making a commitment in advance to buy vaccines if and when they are developed would create incentives for industry to increase investment in research and development. New commercial investment would complement funding of research and development by public and charitable bodies, accelerating the development of vital new vaccines for the developing world. This report presents the proposal from theory to practice, by showing how a commitment can be consistent with ordinary legal and budgetary principles. By creating arrangements that devote the same scientific effort to diseases of the poor...
Making a commitment in advance to buy vaccines if and when they are developed would create incentives for industry to increase investment in resear...
